Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-109 in Impetigo
NCT01803035Phase 2Completed
- Sponsor
- Lytix Biopharma
- Start
- Feb 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of voxvoganan in impetigo, sponsored by Lytix Biopharma. Started Feb 2013; status: completed.
02
Drugs
voxvoganan
03
Conditions
impetigo
Beyond the preview
Go deeper on NCT01803035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803035.